Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $47.4 million.

  • Protagonist Therapeutics' Total Current Liabilities rose 0.82% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year increase of 0.82%. This contributed to the annual value of $47.4 million for FY2024, which is 122.80% up from last year.
  • Protagonist Therapeutics' Total Current Liabilities amounted to $47.4 million in FY2024, which was up 122.80% from $21.3 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Total Current Liabilities ranged from a high of $47.4 million in FY2024 and a low of $21.3 million during FY2023.
  • Its 3-year average for Total Current Liabilities is $33.3 million, with a median of $31.2 million in 2022.
  • As far as peak fluctuations go, Protagonist Therapeutics' Total Current Liabilities plummeted by 31.77% in 2023, and later soared by 122.80% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Total Current Liabilities (Yearly) stood at $40.2 million in 2020, then climbed by 9.38% to $44.0 million in 2021, then decreased by 29.16% to $31.2 million in 2022, then tumbled by 31.77% to $21.3 million in 2023, then surged by 122.80% to $47.4 million in 2024.